Cormorant Asset Management, LP has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $1.43 Billion distributed in 45 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Moon Lake Immunotherapeutics with a value of $428M, Vaxcyte, Inc. with a value of $114M, Arcellx, Inc. with a value of $104M, Longboard Pharmaceuticals, Inc. with a value of $93M, and Edgewise Therapeutics, Inc. with a value of $90.9M.

Examining the 13F form we can see an increase of $128M in the current position value, from $1.3B to 1.43B.

Cormorant Asset Management, LP is based out at Boston, MA

Below you can find more details about Cormorant Asset Management, LP portfolio as well as his latest detailed transactions.

Portfolio value $1.43 Billion
Healthcare: $1.43 Billion

Stock Holdings Table Market Cap. of $10 Billions to $200 Billions

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 45
  • Current Value $1.43 Billion
  • Prior Value $1.3 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 4 stocks
  • Additional Purchases 8 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 11 stocks
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.